Purple Biotech Ltd.
NASDAQ:PPBT
2.84 (USD) • At close April 17, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0.196 | 0 | 0 | 1 | 1 | 1 | 0.1 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0 | 0.196 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit
| 0 | -0 | -0 | -0 | 1 | 1 | 1 | 0.1 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0 | -0.001 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 7.62 | 17.034 | 16.32 | 11.827 | 7.488 | 2.674 | 5.268 | 4.64 | 4.18 | 2.56 | 3.192 | 0.109 |
| General & Administrative Expenses
| 2.935 | 0 | 5.962 | 5.821 | 6.071 | 6.078 | 4.452 | 6.388 | 3.001 | 1.508 | 1.269 | 1.061 |
| Selling & Marketing Expenses
| 0 | 0 | 0.321 | 0.286 | 0.235 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 2.935 | 5.041 | 6.283 | 6.107 | 6.306 | 6.078 | 4.452 | 6.388 | 3.001 | 1.508 | 1.269 | 1.061 |
| Other Expenses
| 0.45 | -44.542 | 0 | 0 | -15.655 | -0.216 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 11.005 | -22.467 | 22.603 | 17.934 | 13.794 | 8.752 | 8.826 | 12.061 | 7.183 | 4.069 | 5.181 | 1.17 |
| Operating Income
| -11.005 | 22.271 | -22.603 | -17.934 | 12.612 | -7.156 | -7.826 | -11.933 | -7.183 | -4.069 | -5.181 | -2.553 |
| Operating Income Ratio
| 0 | 113.741 | 0 | 0 | 12.612 | -7.156 | -7.826 | -119.33 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 3.726 | -42.248 | 0.843 | 0.108 | -15.462 | 1.964 | 2.257 | -1.042 | -4.942 | -0.133 | -0.071 | -0.075 |
| Income Before Tax
| -7.279 | -19.977 | -21.76 | -17.826 | -28.074 | -5.893 | -5.569 | -13.008 | -12.125 | -4.202 | -5.252 | -2.628 |
| Income Before Tax Ratio
| 0 | -102.025 | 0 | 0 | -28.074 | -5.893 | -5.569 | -130.08 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | 0 | 0.877 | 0.637 | -15.669 | 0.216 | 0.207 | -0.71 | 0.006 | -0.076 | 0 | -1.308 |
| Net Income
| -7.24 | -0.02 | -21.668 | -18.384 | -27.999 | -5.85 | -5.2 | -12.272 | -12.125 | -4.202 | -5.252 | -2.628 |
| Net Income Ratio
| 0 | -0.102 | 0 | 0 | -27.999 | -5.85 | -5.2 | -122.72 | 0 | 0 | 0 | 0 |
| EPS
| -0.21 | -0 | -0.12 | -0.1 | -0.24 | -0.3 | -0.37 | -1.3 | -2.11 | -4.37 | -23.45 | -32.05 |
| EPS Diluted
| -0.21 | -0 | -0.12 | -0.1 | -0.16 | -0.3 | -0.37 | -1.3 | -2.11 | -4.37 | -23.44 | -32.03 |
| EBITDA
| -7.052 | -22.225 | -21.433 | -17.383 | -28.41 | -7.638 | -7.726 | -11.929 | -7.043 | -4.198 | -5.231 | -1.197 |
| EBITDA Ratio
| 0 | -113.506 | 0 | 0 | -28.41 | -7.638 | -7.726 | -119.29 | 0 | 0 | 0 | 0 |